Complex mechanism of COVID-19 development
Coronavirus infection (COVID-19) is an acute viral disease, which affects all vital organs and is caused by an RNA-genomic virus of the genus Betacoronavirus of the family Coronaviridae. This virus (SARS-CoV-2) enters the body through the respiratory tract and interacts primarily with Toll-like receptors of epithelial cells of the bronchi, alveoli, intestines and vascular endotheliocytes, as well as with angiotensin-converting enzyme 2 receptors. Toll-like receptors activate nuclear factor Kappa B in these cells, which initiates the formation of many cytokines (“cytokine storm”). SARS-CoV-2 affects type II pneumocytes by causing a termination of surfactant formation and, accordingly, alveolar shrinking and the formation of acute respiratory distress syndrome and also fibrosis on the interalveolar-capillary membrane and the formation of acute respiratory failure. SARS-CoV-2 and cytokines disrupt the function of vascular endothelial cells, which leads to endothelial dysfunction. In microvessels forms a mass formation of microthrombi, which causes the failure of organs and systems. “Cytokine storm” turns into cytokine sepsis with the formation of multiple organ dysfunction syndrome..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Сеченовский вестник - 11(2020), 2, Seite 50-61 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
S. B. Bolevich [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Acute respiratory distress syndrome |
|---|
| doi: |
10.47093/2218-7332.2020.11.2.50-61 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ034943552 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ034943552 | ||
| 003 | DE-627 | ||
| 005 | 20230410115838.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2020 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.47093/2218-7332.2020.11.2.50-61 |2 doi | |
| 035 | |a (DE-627)DOAJ034943552 | ||
| 035 | |a (DE-599)DOAJ4998b12a578d4a61ac714be6228b891b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a S. B. Bolevich |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Complex mechanism of COVID-19 development |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Coronavirus infection (COVID-19) is an acute viral disease, which affects all vital organs and is caused by an RNA-genomic virus of the genus Betacoronavirus of the family Coronaviridae. This virus (SARS-CoV-2) enters the body through the respiratory tract and interacts primarily with Toll-like receptors of epithelial cells of the bronchi, alveoli, intestines and vascular endotheliocytes, as well as with angiotensin-converting enzyme 2 receptors. Toll-like receptors activate nuclear factor Kappa B in these cells, which initiates the formation of many cytokines (“cytokine storm”). SARS-CoV-2 affects type II pneumocytes by causing a termination of surfactant formation and, accordingly, alveolar shrinking and the formation of acute respiratory distress syndrome and also fibrosis on the interalveolar-capillary membrane and the formation of acute respiratory failure. SARS-CoV-2 and cytokines disrupt the function of vascular endothelial cells, which leads to endothelial dysfunction. In microvessels forms a mass formation of microthrombi, which causes the failure of organs and systems. “Cytokine storm” turns into cytokine sepsis with the formation of multiple organ dysfunction syndrome. | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a sars-cov-2 | |
| 650 | 4 | |a corona virus infection | |
| 650 | 4 | |a cytokine | |
| 650 | 4 | |a acute respiratory distress syndrome | |
| 650 | 4 | |a endothelial dysfunction | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a S. S. Bolevich |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Сеченовский вестник |d Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), 2021 |g 11(2020), 2, Seite 50-61 |w (DE-627)DOAJ078607779 |x 26583348 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g number:2 |g pages:50-61 |
| 856 | 4 | 0 | |u https://doi.org/10.47093/2218-7332.2020.11.2.50-61 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/4998b12a578d4a61ac714be6228b891b |z kostenfrei |
| 856 | 4 | 0 | |u https://www.sechenovmedj.com/jour/article/view/241 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2218-7332 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2658-3348 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |e 2 |h 50-61 | ||